ArticleBMC surgery2026
Outcomes of drug-coated balloon combined with stenting vs. stenting alone in the treatment of femoropopliteal artery lesions requiring bailout stenting.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesIn the endovascular treatment of femoropopliteal peripheral arterial disease (PAD), bare metal stents (BMS) are frequently employed as a bailout option. However, in-stent restenosis (ISR) and subsequent reintervention remain a challenge. With the increasing adoption of drug-eluting devices, drug-coated balloons (DCBs) have garnered much attention as an adjunctive strategy. This study aims to evaluate whether the addition of DCBs to bailout stenting improves clinical outcomes.
methodsPatients who underwent endovascular procedures with bailout stenting for femoropopliteal artery (FPA) lesions from January 2019 to September 2023 were retrospectively investigated. The primary endpoints were freedom from clinically driven target lesion revascularization (CD-TLR) and survival rates. Inverse probability of treatment weighting (IPTW) was employed to balance the baseline characteristics, thereby ensuring comparability between the two groups.
resultsThe study cohort included 148 consecutive patients with FPA lesions requiring bailout stenting after plain old balloon angioplasty (POBA). Among them, 118 patients received POBA followed by BMS (POBA + BMS group), and 30 patients received POBA and DCB prior to BMS (POBA + DCB + BMS group). At 1-year follow-up, the POBA + DCB + BMS group demonstrated a significantly higher freedom from CD-TLR (log-rank P = 0.03) compared to the POBA + BMS group, with fewer events (2 vs. 29). However, IPTW-adjusted Cox analysis showed a non-significant trend toward reduced CD-TLR risk (HR 0.43, 95% CI 0.10–1.83; P = 0.26), whereas multivariable Cox analysis demonstrated a significant association (HR 0.20, 95% CI 0.04–0.87; P = 0.03). At 2 years, no significant difference in CD-TLR was observed between groups. No significant differences were observed in mortality or other secondary endpoints.
conclusionsIn patients requiring bailout stenting for FPA lesions, adjunctive DCB use was associated with lower 1-year CD-TLR; however, this finding should be considered hypothesis-generating due to the retrospective design and limited sample size. No sustained benefit was observed at 2 years. No signal for increased short-term mortality was identified, although the study was not powered for safety endpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.